425: NLS Pharmaceutics and Kadimastem Amend Merger Terms for Valuation Clarity

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have signed a sixth amendment to their merger agreement, clarifying the timing for calculating the exchange ratio based on pre-shareholder meeting data.

Summary

• NLS Pharmaceutics Ltd. (the Company) entered into a sixth amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. on July 18, 2025.
• This amendment clarifies that the components used to calculate the Exchange Ratio for the merger will be determined based on information available as of the close of business on the day immediately prior to the Company's extraordinary general meeting of shareholders.
• The amendment defines 'Measurement Date' as the day immediately preceding the Parent Shareholder Meeting.
• It specifies that NLS Pharmaceutics will deliver a 'Parent Estimated Closing Statement' three business days prior to the Measurement Date, detailing estimates for Closing Indebtedness, Closing Cash, Parent Adjusted Cash Amount, and the resulting Merger Consideration.
• This statement will be subject to review and reasonable approval by Kadimastem Ltd.
• The amendment also updates definitions related to 'Fully Diluted Parent Common Stock', 'Fully Diluted Shares', 'Merger Shares', 'Outstanding Shares', 'Parent Valuation', and 'Reference Time' to align with the new Measurement Date.
• The parties remain fully committed to completing the merger as soon as possible and with utmost diligence, actively working to fulfill all related commitments and adhere to regulatory requirements.

Sentiment

Score: 6

Explanation: The document indicates continued progress and commitment towards the merger, with a procedural clarification that should aid in its completion. No negative financial or operational news is present.

Positives

• The parties explicitly state they remain focused on and fully committed to completing the merger as soon as possible and with the utmost diligence, indicating continued progress.
• The amendment clarifies the timing and methodology for calculating the Exchange Ratio, which can reduce uncertainty and streamline the merger process.

Negatives

• The document does not present any explicit negative financial or operational outcomes, focusing solely on a procedural amendment to a merger agreement.

Risks

• Risks related to the companies' ability to complete the merger on the proposed terms and schedule.
• Uncertainties related to the satisfaction of the closing conditions of the merger agreement.
• Risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction.
• Unexpected costs, charges, or expenses resulting from the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger.

Future Outlook

The companies expect to complete the merger, with ongoing efforts to fulfill all commitments and adhere to regulatory requirements. The timing of the Exchange Ratio calculation has been clarified to be based on information immediately preceding the Parent Shareholder Meeting.

Management Comments

• The Parties remain focused on and fully committed to aligning their efforts to completing the merger as soon as possible and with the utmost diligence.
• The Parties are actively working to fulfill all commitments related to the process and adhere to the requirements set forth by all regulatory agents.

Industry Context

This amendment is a procedural step in the ongoing merger between NLS Pharmaceutics, a Swiss-based pharmaceutical company, and Kadimastem, an Israeli biotechnology company. Such amendments are common in complex cross-border merger transactions, reflecting the need to adapt to evolving conditions or clarify terms to ensure successful completion and regulatory compliance.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: The amendment directly impacts how the Exchange Ratio for the merger will be calculated, affecting the number of shares they will receive. They are also required to approve the transaction.
• Management: Responsible for providing estimated financial statements and ensuring compliance with the amended agreement and regulatory requirements.
• Regulatory Authorities: The parties are committed to adhering to requirements set forth by all regulatory agents, indicating ongoing engagement and compliance efforts.

Next Steps

• Obtain shareholder approvals for the transaction.
• Fulfill all closing conditions related to the merger agreement.
• Adhere to requirements set forth by all regulatory agents.
• Publicly release any revisions to forward-looking statements if required by law.

Key Dates

Recommendation

Keywords

Merger Agreement, SEC Filing, NLS Pharmaceutics, Kadimastem, Exchange Ratio, Corporate Governance, Acquisition, Shareholder Meeting, Form 425, Form 6-K